Slowly and steadily, the Danish antibody specialist Genmab has grown into a $27 billion market cap powerhouse driven by cancer research.
Now, Genmab is making moves beyond oncology, announcing Monday a multi-year research deal with the Dutch drugmaker argenx to enter the massive immunology and inflammation market, Genmab CEO Jan van de Winkel told Endpoints News.
The companies will evenly split expenses and potential upside and start researching two undisclosed targets in cancer and immunology, though it could grow to more targets over time, van de Winkel said. Other collaborations with BioNTech and J&J’s Janssen have followed such trajectories.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 165,100+ biopharma pros reading Endpoints daily — and it's free.
"cros" - Google News
April 17, 2023 at 08:37PM
https://ift.tt/tvwTjgW
Japanese CRO buys back penny stock spinout while awaiting FDA ... - Endpoints News
"cros" - Google News
https://ift.tt/FruGWgK
https://ift.tt/J4cVUsF
Bagikan Berita Ini
0 Response to "Japanese CRO buys back penny stock spinout while awaiting FDA ... - Endpoints News"
Post a Comment